Skip to content

Comparing paracetamol and tramadol for pain control in acute pancreatitis

To compare the efficacy paracetamol with tramadol, an opiate analgesic for adequate analgesia in patient with acute pancreatitis- a pilot study

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042361
Enrollment
40
Registered
2022-05-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K852- Alcohol induced acute pancreatitis

Interventions

Intervention1: Paracetamol: Patients will be randomized to receive either injection paracetamol 100 mg/hour infusion or injection tramadol 100 mg given intravenously at 8-hour intervals for 24 hours C

Sponsors

AIIMS Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with AP diagnosed as per the revised Atlanta classification Abdominal pain at enrollment Hospitalization within 7 days of onset of pain Patients who are willing to give consent

Exclusion criteria

Exclusion criteria: Age 75 years Patients with grade 2 organ failure at enrollment as defined by modified Marshall grading Patients with known coronary artery disease Patients in altered sensorium Patients with a serum creatinine > 1.5 mg/dL Patients with evidence of chronic pancreatitis Patients with past history of allergy to tramadol or paracetamol Patients with suspected pancreatic carcinoma Refusal to give consent

Design outcomes

Primary

MeasureTime frame
The difference in the efficacy of paracetamol and tramadol for pain relief was the primary outcome, which was measured by the total dose of pentazocine required as the rescue analgesic, pain-free period, and the total number of demands of the rescue analgesicTimepoint: The study will end at 50 hours, i.e., 2 hours after the last dose of the analgesic

Secondary

MeasureTime frame
Difference in the adverse events between the 2 groups will be the secondary outcomeTimepoint: The study will end at 50 hours, 2 hours after the last dose of the analgesic

Countries

India

Contacts

Public ContactHemanta Kumar Nayak

AIIMS Bhubaneswar

medgast_hemanta@aiimsbhubaneswar.edu.in7008927243

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026